Study of High Sensitive Troponin-I Level in End-stage Renal Disease Patients Receiving Hemodialysis
NCT ID: NCT02572466
Last Updated: 2016-01-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
207 participants
OBSERVATIONAL
2015-02-28
2015-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The current cTnI detecting test has developed more and more high sensitive(called "high-sensitive troponin-I; hsTnI") which can detected in the range 10-50,000 pg / ml (ng / L) \[6\], and it can detected cTnI level even in normal people unlike cTnI, which only reported positive or negative or lower than the limit of detection. Due to ARCHITECT stat High sensitive Troponin-I (Abbott diagnostic) capabilities, hsTnI level can be detected in normal people up to 96 percent.\[7\] The reference range of hsTnI which has been researched by Apple FS, et al.(2012) studying the 19 types of cardiac troponin I and T measurement was established. The 99th percentile values for general healthy population without hypertension, diabetes, kidney disease and myocardial infarction, aged 18-64 years was 36 ng / L in men (N = 272), 15 ng / L in women (N = 252) \[7\].
However, research to find the reference of hsTnI in some groups , especially in patients with kidney disease is still limited and the diagnosis of acute myocardial infarction also use the 99th percentile as the reference source which was researched in healthy population\[7\] which makes it difficult to interpret. Sometimes doctors may concluded that patients with rising hsTnI because of kidney disease. According to the research in the next section, there are both support and against in this idea. Therefore, the researchers aim to study hsTnI in patients with end-stage renal disease received hemodialysis compare with normal population.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ESRD group
1. Aged 18 years or older.
2. was diagnosed as End-stage renal disease for more than one year.
3. Attend hemodialysis 3 times a week consistently for more than 6 months.
4. Hemodialysis with Kt/V \> 1.2
5. No urine output or is less than 500 ml per day.
6. No symptoms of myocardial infarction Or were hospitalized with the similar diagnosis during the two weeks.
Hemodialysis
ESRD group received long-term hemodialysis
Control group
1. Aged 18 years or older.
2. without kidney disease (eGFR \> 60 ml/min/1.73m2)
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Hemodialysis
ESRD group received long-term hemodialysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* was diagnosed as End-stage renal disease for more than one year.
* Attend hemodialysis 3 times a week consistently for more than 6 months.
* Hemodialysis with Kt/V \> 1.2
* No urine output or is less than 500 ml per day.
* No symptoms of myocardial infarction Or were hospitalized with the similar diagnosis during the two weeks.
Exclusion Criteria
* Has symptoms of myocardial infarction while receiving dialysis
* Has the abnormal symptom (fever, chill, low BP) While receiving dialys
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chulalongkorn University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Khajohn Tiranathanagul
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Khajohn Tiranathanagul, MD
Role: PRINCIPAL_INVESTIGATOR
Chulalongkorn University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
King Chulalongkorn Memorial Hospital
Bangkok, Bangkok, Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
271/57
Identifier Type: -
Identifier Source: org_study_id